Avinger Seeks 510(k) Clearance for Pantheris SV Lumivascular Device

 

August 30, 2018—Avinger, Inc. announced the submission of an application to the FDA for 510(k) clearance of the Pantheris SV (small vessel) Lumivascular atherectomy system. The device is an extension of the company's Pantheris family of image-guided atherectomy catheters for the treatment of peripheral artery disease.

According to the company, the Pantheris SV is designed with a lower profile and longer length for treating lesions in smaller diameter vessels and more distal regions of the vasculature. The Pantheris SV incorporates key improvements introduced to the platform with the clearance of the next-generation Pantheris system that was announced in May 2018. Improvements include a stiffer shaft for increased pushability, a refined optical coherence tomography imaging system, a more robust nosecone, and an enhanced cutter design.

On August 29, Avinger announced the issuance of a United States patent (No. 10,052,125), “Atherectomy Catheter With Laterally-Displaceable Tip,” for the Pantheris system. The patent describes an atherectomy catheter including real-time image guidance using optical coherence tomography, a displaceable tip, and a balloon to urge the catheter’s cutting element into the tissue to be removed. These are all key features of the Pantheris atherectomy system, noted the company.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.